Overview
Navigating the Rapidly Evolving Classification and Treatment Landscape of Secondary AML Subtypes: Modeling Best Practices for Early Identification and Individualized Care
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Are you optimally treating secondary AML subtypes per latest evidence on selection of therapies? To optimize treatment, clinicians must not only have current knowledge of the up-to-date classification and risk stratification strategies, but the operational frameworks to effectively translate this latest evidence into treatment selection practices. Assess your current practices, review the latest evidence and best practices shared by leaders in the field, and create your own action plan to ensure your patients are benefitting from the latest advancements in care.
This program is intended for medical hematologists/oncologists, pathologists, advanced practice clinicians, oncology nurses, and other members of the multidisciplinary/multispecialty team who treat patients with sAML.
Secondary acute myeloid leukemia (sAML) typically emerges as a consequence of a prior clonal disorder within the hematopoietic system. This condition commonly results from myelodysplasia-related changes (referred to as AML-MRC) or exposure to cytotoxic chemotherapy or radiation therapy used to treat unrelated malignancies, known as therapy-related AML (t-AML). In terms of burden, prognostic factors, diagnostic criteria, and treatments, substantial differences exist between sAML and de novo AML. Further, sAML has been linked to less favorable outcomes when compared with de novo AML. Historically, the treatment of sAML was very limited, as patients typically did not receive desirable outcomes from older agents. Fortunately, the sAML treatment paradigm is beginning to shift due to new and emerging therapies. Clinicians must be aware of these practice-changing developments and tailored management strategies to significantly impact patient outcomes.
Upon completion of this activity, learners will be able to:
• Identify the prognostic factors in secondary acute myeloid leukemia (sAML) that contribute to its heightened severity compared with patients diagnosed with de novo AML
• Outline the criteria for diagnosing sAML
• Evaluate the latest clinical trial findings for new and emerging therapies that have the potential to significantly enhance treatment results in patients with sAML
• Integrate novel agents into sAML treatment plans based on recent clinical evidence and individualized factors
• Identify the prognostic factors in secondary acute myeloid leukemia (sAML) that contribute to its heightened severity compared with patients diagnosed with de novo AML
• Outline the criteria for diagnosing sAML
• Evaluate the latest clinical trial findings for new and emerging therapies that have the potential to significantly enhance treatment results in patients with sAML
• Integrate novel agents into sAML treatment plans based on recent clinical evidence and individualized factors
Provided by The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL).
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Courtney DiNardo, MD, MSCE
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Jeffrey Lancet, MD
Department Chair
Malignant Hematology
Moffitt Cancer Center
Tampa, FL
The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others, are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
The following financial relationships have been provided:
Courtney DiNardo, MD (Chair)
Honoraria-AbbVie Inc.|Honoraria-Rigel|Honoraria-Daiichi Sankyo, Inc.|Honoraria-Gilead Sciences, Inc. (Relationship has ended)|Honoraria-Genentech, Inc.|HonorariaAstellas Scientific and Medical Affairs, Inc. (Relationship has ended)|Honoraria-Bristol-Myers Squibb Company|Honoraria-GlaxoSmithKline|Honoraria-Jazz Pharmaceuticals|Honoraria-Novartis Pharmaceuticals Corporation (Relationship has ended)|Honoraria-Servier Pharmaceuticals|Honoraria-Immunogen (Relationship has ended)|Consulting FeeSchrodinger|Advisor-Ellipses
Jeffrey Lancet, MD (Chair)
Consulting Fee-Treadwell Therapeutics (Relationship has ended)|Grant or research support-Prescient Therapeutics (Relationship has ended)|Grant or research support-Biomea Fustion|Grant or research support-Jasper Therapeutics|Grant or research support-Moderna (Relationship has ended)|Consulting Fee-Karyopharm Therapeutics (Relationship has ended)|Consulting Fee-AbbVie Inc. (Relationship has ended)
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Novel combinations and agents (idasanutlin and eprenetapopt) under investigation for AML
The University of Texas MD Anderson Cancer Center and ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learner requires the speaker to disclose that a product is not labeled for the use under discussion.
The following planning committee members have financial relationships to disclose:
Courtney DiNardo, MD (Chair)
Honoraria-AbbVie Inc.|Honoraria-Rigel|Honoraria-Daiichi Sankyo, Inc.|Honoraria-Gilead Sciences, Inc. (Relationship has ended)|Honoraria-Genentech, Inc.|HonorariaAstellas Scientific and Medical Affairs, Inc. (Relationship has ended)|Honoraria-Bristol-Myers Squibb Company|Honoraria-GlaxoSmithKline|Honoraria-Jazz Pharmaceuticals|Honoraria-Novartis Pharmaceuticals Corporation (Relationship has ended)|Honoraria-Servier Pharmaceuticals|Honoraria-Immunogen (Relationship has ended)|Consulting FeeSchrodinger|Advisor-Ellipses
Jeffrey Lancet, MD (Chair)
Consulting Fee-Treadwell Therapeutics (Relationship has ended)|Grant or research support-Prescient Therapeutics (Relationship has ended)|Grant or research support-Biomea Fustion|Grant or research support-Jasper Therapeutics|Grant or research support-Moderna (Relationship has ended)|Consulting Fee-Karyopharm Therapeutics (Relationship has ended)|Consulting Fee-AbbVie Inc. (Relationship has ended)
No financial relationships to disclose:
KarryAnne Belanger, PhD
Karen Catino
Katlyn Cooper
Danya Garner, PhD, RN, MPD-BC, OCN, CCRN-K
Danya Garner, PhD, RN, MPD-BC, OCN, CCRN-K
Katie Hacias
Lisa Keckich
Ritesh Kothari
Natasha Mitchner, PhD
Laurie Novoryta
McKenna Reinhard
Vanessa Senatore
Cicely Simon
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Texas MD Anderson Cancer Center designates this enduring material will award 1.0 Nursing Contact Hours.
Completion of this activity, including the pretest, posttest and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
